Shanghai Aladdin Biochemical Technology Co (688179) Fair Value & Analysis
Basic Materials · CN · Market cap 7.5B CNY
Analysis
Shanghai Aladdin Biochemical Technology Co (688179) currently trades at ¥22.78, while our model-based Fair Value estimate is ¥4.79 — implying the stock looks roughly 79.0% overvalued today. We read business quality at 84/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Shanghai Aladdin Biochemical Technology Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of scientific research reagents in China and internationally. It offers chemistry and biochemicals reagents, including blocks, ligands, catalysts, chemical synthesis, laboratory chemicals, chemical biology, analytical standards, CVD and ALD precursors, and stable isotopes; material science solutions for energy, electronic, and biomedical materials; and small molecules, such as compound libraries, ligand families, antibody-drug conjugates, and protein degradation-targeting chimeras, as well as classification by signaling pathway, target toxin, and disease. The company also provides life sciences comprising protein, antibody, and molecular, protein, and cell biology; GMP-grade products, which include bioactive small molecules, grade protein, upstream process chemicals, downstream process and formulation chemicals, and culture medium and buffer ra…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.